DeepMed Research

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

Phase 2

Completed

Conditions: Partial Onset Seizures

Interventions: Drug: Placebo

First Posted Date: 2010-06-22

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis

Target Recruit Count: 93

Registration Number: NCT01147003

Locations: 🇺🇸
AMO Corporation, Tallahassee, Florida, United States
🇺🇸
Thomas Jefferson University, Dept. of Psychiatry & Neurology, Philadelphia, Pennsylvania, United States
🇺🇸
Medical Center of the Rockies, Loveland, Colorado, United States

and more 13 locations

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: FTY720

First Posted Date: 2010-05-21

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis

Target Recruit Count: 2417

Registration Number: NCT01127750

Locations: 🇩🇪
Neuroscience Research of the Berkshires, Krefeld, Germany
🇬🇧
Novartis Investigational Site, Truro, United Kingdom
🇩🇪
Novarris Investigative Site, Berlin, Germany

and more 3 locations

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

Phase 1

Completed

Conditions: Typhoid Fever

Interventions: Biological: NVGH Vi-CRM197
Biological: Typherix

First Posted Date: 2010-05-14

Last Posted Date: 2014-01-17

Lead Sponsor: Novartis

Target Recruit Count: 50

Registration Number: NCT01123941

Locations: 🇧🇪
Center for the Evaluation of Vaccination (CEV), Antwerp, Wilrijk (Antwerp), Belgium

Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ

First Posted Date: 2010-04-29

Last Posted Date: 2013-12-06

Lead Sponsor: Novartis

Target Recruit Count: 347

Registration Number: NCT01113047

Locations: 🇩🇪
Investigative Site, Pirna, Germany

Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

Phase 3

Withdrawn

Conditions: Uveitis

Interventions: Biological: AIN457
Biological: Placebo

First Posted Date: 2010-04-13

Last Posted Date: 2020-09-29

Lead Sponsor: Novartis

Registration Number: NCT01103024

Locations: 🇨🇭
Novartis Investigative Site, Bern, Switzerland
🇯🇵
Novartis Investigational Site, Kyoto, Japan
🇺🇸
Texas Retina Associates, Arlington, Texas, United States

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: AFQ056 with L-dopa
Drug: Placebo

First Posted Date: 2010-03-24

Last Posted Date: 2020-12-23

Lead Sponsor: Novartis

Target Recruit Count: 23

Registration Number: NCT01092065

Locations: 🇺🇸
The Parkinsons Institute, Sunnyvale, California, United States
🇺🇸
Colorado Neurological Institute, Englewood, Colorado, United States
🇺🇸
University of Kansas Medical Center - Parkinson's Disease and Movement Disorders Center, Kansas City, Kansas, United States

and more 1 locations

Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain

Phase 4

Completed

Conditions: Neuropathic Pain

Interventions: Drug: Carbamazepine

First Posted Date: 2010-03-19

Last Posted Date: 2017-07-13

Lead Sponsor: Novartis

Target Recruit Count: 123

Registration Number: NCT01089855

Locations: 🇲🇦
Novartis Investigational Site, Rabat, Morocco

12-week Efficacy of Indacaterol

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol 75 μg
Drug: Placebo to indacaterol

First Posted Date: 2010-02-22

Last Posted Date: 2011-08-19

Lead Sponsor: Novartis

Target Recruit Count: 323

Registration Number: NCT01072448

Locations: 🇺🇸
Novartis Investigative site, Greer, South Carolina, United States
🇺🇸
Novartis Investigator Site, Tacoma, Washington, United States
🇺🇸
Novartis Investigative Site, Newport News, Virginia, United States

Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients

Phase 3

Completed

Conditions: Hyperphosphatemia
Chronic Kidney Disease

Interventions: Drug: SBR759A

First Posted Date: 2010-02-17

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis

Target Recruit Count: 115

Registration Number: NCT01069692

Locations: 🇮🇹
Novartis Investigator Site, Lucca, Italy
🇮🇹
Novartis Investigative Site, Siena, Italy

Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension

Phase 4

Completed

Conditions: Stage II Hypertension

First Posted Date: 2010-02-17

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis

Target Recruit Count: 230

Registration Number: NCT01070030

Locations: 🇹🇭
Investigative Site, Nakhon Ratchasima, Thailand

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy